Category Archives: Genetics

FAQ-4 19- What Chance Stem Cells Can Help Me After Stem Cell Therapy?
youtu.be Whether differentiated or undifferentiated, from sheep stem cells or from rabbit; delivered frozen or fresh, today #39;s stem cell therapies are showing real promise and helping HIV-AIDS sufferers around the world, today! Cautious not to claim they can cure ANYTHING, today #39;s ethical clinics offer hope for AIDS-HIV sufferers worldwide, although the one Thai clinic licensed by the German stem cell technique is in Bangkok. For information to help you make an informed, personal decision, check out StemCell-Asia.info today.From:Harvey WallbangerViews:1 0ratingsTime:01:38More inPeople Blogs

See the article here:
FAQ-4 19- What Chance Stem Cells Can Help Me After Stem Cell Therapy? - Video

FAQ-4 19- What Chances for Stem Cell Success When I Get Stem Cell Therapy?
youtu.be Whether as differentiated or undifferentiated, whether from sheep stem cells or from rabbit stem cells; delivered frozen or fresh, today #39;s stem cell therapies are showing real promise and helping HIV-AIDS sufferers around the world, today! Cautious not to claim they can cure ANYTHING, today #39;s ethical clinics offer hope for AIDS-HIV sufferers worldwide, although the one Thai clinic licensed by the German stem cell technique is in Bangkok. For information to help you make an informed, personal decision, check out StemCell-Asia.info today.From:VeteransRecallViews:0 0ratingsTime:01:38More inPeople Blogs

More:
FAQ-4 19- What Chances for Stem Cell Success When I Get Stem Cell Therapy? - Video

[RMS] C-Class Stem Cell Processing Center (SPC)
C-Type Member practice stem cell therapy with setting up C-class Stem cell Processing Center. Single platform with necessary equipments (including the ones for quality control tests) built in single space for the production of Chondron processing room, preparation room, utility room.From:SewonCellontechViews:1 0ratingsTime:00:46More inHowto Style

See the rest here:
[RMS] C-Class Stem Cell Processing Center (SPC) - Video

Stem Cell Therapy for osteoarthritis Cosmetic Surgery Thailand Review - Urban Beauty Thailand
Plastic Surgery Thailand Cost Reviews Adipose-derived stemcell fat graft + PRP + Fat transfer for natural augmentation on all part of body such as Face, Breast, Butt, Hand etc. Adistem is originally and can deliver Stemcell for cell survial more than 300millions cell.Compare with other methods such as CAL, Adistem is most Cell Survival among others result is permanantly. Normally, the cost is around 350000baht/appx $11667usd but we can offer as $9000usd/appx 270000THB all inclusive with 5 nights facilities. Urban Beauty Thailand is a bespoke One-Stop Travel and Beauty Solution. Arranging the best medical tourism package for you, from your flights, to whichever Cosmetic Surgery, Beauty Treatments or Dental Treatments are right for you, at the right treatment center, whether in Bangkok, Phuket, Koh Samui, or Pattaya. We also arrange excursions and holiday activities during your stay. Cosmetic surgery Thailand, Plastic surgery Thailand cost reviews. Provide FREE Consultation olivia@urbanbeautythailand.com http://www.urbanbeautythailand.comFrom:UrbanBeautyThaiViews:0 1ratingsTime:07:21More inTravel Events

More here:
Stem Cell Therapy for osteoarthritis Cosmetic Surgery Thailand Review - Urban Beauty Thailand - Video

FAQ-3 of 19 -How Do Stem Cells Work in Stem Cell Therapy?
youtu.be Short video describing how stem cells home in on their injured organs, find their place and then differentiate into the cells that the hurt or diseased or dysfunctional organ NEEDS. For more on this and how stem cells MIGHT help you or your loved one, go to StemCell-Asia.info now.From:Karridine1Views:0 0ratingsTime:01:06More inScience Technology

Read this article:
FAQ-3 of 19 -How Do Stem Cells Work in Stem Cell Therapy? - Video

FAQ-4 of 19: What Is My Chance of Success With Stem Cells in Stem Cell Therapy
youtu.be When considering stem cell treatment, it is natural to wonder what one #39;s chances of success are. This short video explains several key factors in assuring successful stem cell therapy. For more detailed information, visit StemCell-Asia.infoFrom:Karridine1Views:0 0ratingsTime:01:28More inPeople Blogs

See the original post here:
FAQ-4 of 19: What Is My Chance of Success With Stem Cells in Stem Cell Therapy - Video

FAQ-4 of 19: What Chance That Stem Cells Will Help Me When I Get Stem Cell Therapy
youtu.be When considering stem cell treatment, it is only natural to wonder what one #39;s chances of success are. This brief video explains several of the key factors in assuring successful stem cell therapy. For more detailed information, visit StemCell-Asia.infoFrom:John PepperViews:0 0ratingsTime:01:28More inPeople Blogs

Read more here:
FAQ-4 of 19: What Chance That Stem Cells Will Help Me When I Get Stem Cell Therapy - Video

REYKJAVIK, Iceland, October 4, 2012 /PRNewswire/ --

ORF Genetics announced today that the company has added endotoxin- and animal-free human Fibroblast Growth Factor Basic (FGF basic) and mouse Leukemia Inhibitory Factor (mouse LIF) to its portfolio of growth factors for stem cell research.

Most growth factors applied in stem cell research today are made in E. coli bacteria, which produce endotoxins that can have adverse effect on stem cell cultures. Other manufacturers of growth factors have various methods to remove these endotoxins, but traces inevitably remain, which can lead to increased death rate of cells and other suboptimal effects in cell cultures. Other growth factors on the market today are made by animal cells. However, most stem cell researchers prefer to use growth factors of non-animal origin to exclude risks of viral contamination and the inclusion of growth factor homologs.

This has led to a market demand for alternative sources of animal-free growth factors, void of endotoxins. ORF Genetics' unique growth factors are produced in the seeds of the barley plant, which does not produce any endotoxins or other substances toxic to mammalian cells.

FGF basic and mouse LIF are key growth factors for the cultivation of their respective stem cells, i.e. FGF basic for human stem cells and mouse LIF for mouse stem cells. Each protein is used to expand the stem cells' populations before researchers make them differentiate into various cell types, such as heart, liver or neural cells.

"ORF Genetics has built a reputation for offering the first plant-made, endotoxin-free and animal-free growth factor portfolio for stem cell researchers. As we are producing these growth factors in our novel plant expression system ORFEUS, we are very happy to be able to offer these high quality growth factors at more efficient prices than market leaders," said Bjrn rvar, CEO of ORF Genetics.

ORF Genetics is a world leader of plant made growth factors and offers a portfolio of endotoxin- and animal-free growth factors for human stem cell research. The company's production takes place in a biorisk-free production system in barley, bypassing conventional bacteria and animal cell production systems. The cultivation of barley takes place in greenhouses in inert volcanic pumice, using renewable geothermal energy.

For more information please contact:

Dr. Hakon Birgisson, Director of Global Market Development Tel: +354-821-1585 email:hakon.birgisson@orfgenetics.com

Read more here:
ORF Genetics to Offer endotoxin- and Animal-free FGFb and mLIF for Stem Cell Research

CAMBRIDGE, Mass. & BOTHELL, Wash.--(BUSINESS WIRE)--

Seattle Genetics, Inc. (SGEN) and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502), today announced the completion of patient enrollment in a phase III clinical trial of ADCETRIS (brentuximab vedotin) for post-transplant Hodgkin lymphoma (HL) patients. The phase III trial, also known as the AETHERA trial, is evaluating ADCETRIS versus placebo for the treatment of patients at high risk of residual Hodgkin lymphoma following autologous stem cell transplant (ASCT). ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30, a defining marker of classical HL.

We are pleased to complete the enrollment of this important phase III trial, evaluating the use of ADCETRIS for Hodgkin lymphoma patients who are at high risk of residual disease following an ASCT, said Thomas C. Reynolds, M.D., Ph.D., Chief Medical Officer of Seattle Genetics. The AETHERA trial is designed to provide the medical community with valuable insight into the potential for ADCETRIS to consolidate responses in Hodgkin lymphoma patients following a transplant, and will be the first data on the use of ADCETRIS in a maintenance-type setting. We anticipate data from this trial will be available in late 2013 or early 2014.

Completing enrollment of the AETHERA trial in the post-transplant Hodgkin lymphoma patient population at high risk for residual disease is a significant milestone for our ADCETRIS clinical development program, said Karen Ferrante, M.D., Chief Medical Officer, Millennium. We look forward to continuing to work with our partner Seattle Genetics to determine the potential benefit of this targeted treatment in other CD30-expressing tumors.

The AETHERA trial is a randomized, double-blind, placebo-controlled phase III study, comparing progression-free survival in 329 post-ASCT patients receiving ADCETRIS to those receiving placebo. Patients must be at high risk for residual HL, defined as those with a history of refractory HL, those who relapse or progress within one year from receiving front-line chemotherapy and/or those who have disease outside of the lymph nodes at the time of pre-ASCT relapse. Secondary endpoints of the trial include overall survival, safety and tolerability. Patients receive ADCETRIS every three weeks for up to approximately one year. This international multi-center trial is being conducted in the United States, Europe and Russia.

About ADCETRIS

ADCETRIS (brentuximab vedotin) is an ADC comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE), utilizing Seattle Genetics proprietary technology. The ADC employs a linker system that is designed to be stable in the bloodstream but to release MMAE upon internalization into CD30-expressing tumor cells.

ADCETRIS received accelerated approval from the U.S. Food and Drug Administration (FDA) for two indications: (1) the treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplant (ASCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not ASCT candidates, and (2) the treatment of patients with systemic anaplastic large cell lymphoma (sALCL) after failure of at least one prior multi-agent chemotherapy regimen. The indications for ADCETRIS are based on response rate. There are no data available demonstrating improvement in patient-reported outcomes or survival with ADCETRIS.

ADCETRIS is not approved for use outside the United States. The marketing authorization application for ADCETRIS in relapsed or refractory Hodgkin lymphoma and sALCL, filed by Takeda Global Research & Development Centre (Europe), was accepted for review by the European Medicines Agency (EMA) in June 2011. In July 2012, the Committee for Medicinal Products for Human Use (CHMP) of the EMA issued a positive opinion for the conditional approval of ADCETRIS, supporting an approval decision in the European Union.

Seattle Genetics and Millennium are jointly developing ADCETRIS. Under the terms of the collaboration agreement, Seattle Genetics has U.S. and Canadian commercialization rights and the Takeda Group has rights to commercialize ADCETRIS in the rest of the world. Seattle Genetics and the Takeda Group are funding joint development costs for ADCETRIS on a 50:50 basis, except in Japan where the Takeda Group will be solely responsible for development costs.

View original post here:
Seattle Genetics and Millennium Complete Enrollment in Phase III AETHERA Trial of ADCETRIS® for Post-Transplant ...

While $34.7 million is a touch more than $34.5 million, that's not exactly huge quarter-over-quarter growth from Seattle Genetics' (Nasdaq: SGEN) Adcetris.

Still, investors seem to be shaking off the lackluster growth, and for good reason: Sales of Adcetris -- a drug for treating relapsed Hodgkin lymphoma and anaplastic large-cell lymphoma -- are a very small part of the long-term success of Seattle Genetics.

The light growth seems to be the result of declining business at academic centers, where sales dropped off as patients stopped treatment because they finished their therapy cycles or had a strong enough response to undergo a stem-cell transplant.

The number of community doctors using the drug increased in the second quarter, which is good news for the sales trajectory, as most of the lymphoma patients for whom Adcetris is appropriate are seen in the community setting.

Don't expect much growth in the second half, though; management is guiding for sales of $140 million to $150 million in 2012 -- either flat or a 17% increase from the first half of the year to the second half.

Seattle Genetics lost $12.3 million on a GAAP basis in the quarter but didn't actually burn any cash. In fact, the cash, cash equivalents, and investments increased by $21.5 million during the quarter. I don't know how long investors can expect that to continue, as the biotech is still using product manufactured prior to approval.

Of course, aside from Adcetris, Seattle Genetics can bring in cash by licensing out its antibody-drug conjugate technology, which has attracted some big names, including Roche, GlaxoSmithKline (NYSE: GSK) , Pfizer (NYSE: PFE) , and Abbott Labs (NYSE: ABT) .

Internally, Seattle Genetics' future depends on expanding the use of Adcetris into frontline setting for the two lymphomas it's currently approved to treat, as well as other types of cancer. The potential there towers over the $150 million Seattle Genetics will bring in this year.

Interested in new technology? Check out the Fool's new report, "The Next Trillion Dollar Revolution." Claim your free copy by clicking here.

Read the original:
A Growth-Free Quarter -- and That's OK